• Something wrong with this record ?

Do AMPA/kainate antagonists possess potential in the treatment of addiction? Evidence from animal behavioural studies

M. Hrickova, J. Ruda-Kucerova

. 2025 ; 138 (-) : 111355. [pub] 20250403

Language English Country England, Great Britain

Document type Journal Article, Review

Substance addiction is a complex mental disorder with significant unmet treatment needs, especially in terms of effective medications. Craving in addiction is closely linked to the interaction between dopamine and glutamate in the brain's reward pathway. Therefore, drugs targeting glutamatergic signaling may have potential for treatment. This review examines the potential of AMPA/kainate glutamatergic receptor antagonists in reducing addictive-like behaviours in experimental rodents. To this end, the text summarizes the behavioural results of preclinical studies on stimulant substances (cocaine, amphetamine, methamphetamine, MDMA), nicotine, opioids (morphine and heroin), and alcohol. These experiments employ various protocols and routes of administration, using different strains of mice and rats. The main behavioural methods used in the research include behavioural sensitization protocols, drug-induced locomotor activity assessments, conditioned behaviours, and operant self-administration models. The reviewed literature demonstrates the benefit of AMPA/kainate antagonists, mainly in the most studied cocaine dependence, and particularly in attenuating cocaine-seeking behaviour via microinjection into the nucleus accumbens core. Regarding other addictive substances, despite some conflicting results, there is a substantial body of literature showing promising outcomes following systemic or intracerebral administration of AMPA/kainate antagonists. The main issue is the variability of the research protocols used across laboratories, including differences in animal species, strains, sex and environmental conditions. Moreover, each addictive substance exhibits distinct mechanisms of action and addiction development, rendering the pursuit of a universal drug for addiction treatment unrealistic. Nevertheless, AMPA/kainate antagonists seem to have potential as a supportive treatment in addiction to cocaine as well as other substances.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc25016185
003      
CZ-PrNML
005      
20250731091600.0
007      
ta
008      
250708e20250403enk f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.pnpbp.2025.111355 $2 doi
035    __
$a (PubMed)40187601
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Hrickova, Maria $u Department of Pharmacology, Faculty of Medicine, Masaryk University, Brno, Czech Republic
245    10
$a Do AMPA/kainate antagonists possess potential in the treatment of addiction? Evidence from animal behavioural studies / $c M. Hrickova, J. Ruda-Kucerova
520    9_
$a Substance addiction is a complex mental disorder with significant unmet treatment needs, especially in terms of effective medications. Craving in addiction is closely linked to the interaction between dopamine and glutamate in the brain's reward pathway. Therefore, drugs targeting glutamatergic signaling may have potential for treatment. This review examines the potential of AMPA/kainate glutamatergic receptor antagonists in reducing addictive-like behaviours in experimental rodents. To this end, the text summarizes the behavioural results of preclinical studies on stimulant substances (cocaine, amphetamine, methamphetamine, MDMA), nicotine, opioids (morphine and heroin), and alcohol. These experiments employ various protocols and routes of administration, using different strains of mice and rats. The main behavioural methods used in the research include behavioural sensitization protocols, drug-induced locomotor activity assessments, conditioned behaviours, and operant self-administration models. The reviewed literature demonstrates the benefit of AMPA/kainate antagonists, mainly in the most studied cocaine dependence, and particularly in attenuating cocaine-seeking behaviour via microinjection into the nucleus accumbens core. Regarding other addictive substances, despite some conflicting results, there is a substantial body of literature showing promising outcomes following systemic or intracerebral administration of AMPA/kainate antagonists. The main issue is the variability of the research protocols used across laboratories, including differences in animal species, strains, sex and environmental conditions. Moreover, each addictive substance exhibits distinct mechanisms of action and addiction development, rendering the pursuit of a universal drug for addiction treatment unrealistic. Nevertheless, AMPA/kainate antagonists seem to have potential as a supportive treatment in addiction to cocaine as well as other substances.
650    _2
$a zvířata $7 D000818
650    12
$a AMPA receptory $x antagonisté a inhibitory $7 D018091
650    12
$a poruchy spojené s užíváním psychoaktivních látek $x farmakoterapie $x metabolismus $7 D019966
650    12
$a receptory kyseliny kainové $x antagonisté a inhibitory $7 D018092
650    12
$a antagonisté excitačních aminokyselin $x terapeutické užití $x farmakologie $7 D018691
650    _2
$a lidé $7 D006801
650    12
$a návykové chování $x farmakoterapie $7 D016739
650    12
$a chování zvířat $x účinky léků $7 D001522
655    _2
$a časopisecké články $7 D016428
655    _2
$a přehledy $7 D016454
700    1_
$a Ruda-Kucerova, Jana $u Department of Pharmacology, Faculty of Medicine, Masaryk University, Brno, Czech Republic. Electronic address: jkucer@med.muni.cz
773    0_
$w MED00003930 $t Progress in neuro-psychopharmacology & biological psychiatry $x 1878-4216 $g Roč. 138 (20250403), s. 111355
856    41
$u https://pubmed.ncbi.nlm.nih.gov/40187601 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20250708 $b ABA008
991    __
$a 20250731091555 $b ABA008
999    __
$a ok $b bmc $g 2366785 $s 1253310
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2025 $b 138 $c - $d 111355 $e 20250403 $i 1878-4216 $m Progress in neuro-psychopharmacology & biological psychiatry $n Prog Neuropsychopharmacol Biol Psychiatry $x MED00003930
LZP    __
$a Pubmed-20250708

Find record

Citation metrics

Loading data ...

Archiving options

Loading data ...